MDPI and ACS Style
Fleischmann, M.; Mandal, R.; Kostova, I.; Raab, M.; Sanhaji, M.; Hehlgans, S.; Diefenhardt, M.; Rödel, C.; Fokas, E.; Strebhardt, K.;
et al. Prognostic Impact of Caspase-8, CDK9 and Phospho-CDK9 (Thr 186) Expression in Patients with Uterine Cervical Cancer Treated with Definitive Chemoradiation and Brachytherapy. Cancers 2022, 14, 5500.
https://doi.org/10.3390/cancers14225500
AMA Style
Fleischmann M, Mandal R, Kostova I, Raab M, Sanhaji M, Hehlgans S, Diefenhardt M, Rödel C, Fokas E, Strebhardt K,
et al. Prognostic Impact of Caspase-8, CDK9 and Phospho-CDK9 (Thr 186) Expression in Patients with Uterine Cervical Cancer Treated with Definitive Chemoradiation and Brachytherapy. Cancers. 2022; 14(22):5500.
https://doi.org/10.3390/cancers14225500
Chicago/Turabian Style
Fleischmann, Maximilian, Ranadip Mandal, Izabela Kostova, Monika Raab, Mourad Sanhaji, Stephanie Hehlgans, Markus Diefenhardt, Claus Rödel, Emmanouil Fokas, Klaus Strebhardt,
and et al. 2022. "Prognostic Impact of Caspase-8, CDK9 and Phospho-CDK9 (Thr 186) Expression in Patients with Uterine Cervical Cancer Treated with Definitive Chemoradiation and Brachytherapy" Cancers 14, no. 22: 5500.
https://doi.org/10.3390/cancers14225500